Rick Doblin: MDMA for PTSD

Rick Doblin, Ph.D., founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), talks about how research into MDMA and other psychedelics as treatments for PTSD and other illnesses is helping pave the way from banned drugs to legal medicines.

To learn more, visit www.maps.org or www.mdmaptsd.org.

Rick Doblin, Ph.D. MAPS Executive Director
Paving the Way From Banned Drug to Legal Medicine

Psychedelics have been used by tens of millions, hundreds of millions of people

so we know the risks of psychedelics.

We have hundreds of millions of dollars already spent by the governments on the risks

and we don't have to do that research again. It's in the public domain.

For roughly $10 million focused very narrowly on an ever expanding series of studies

looking at safety of, and efficacy of, psychedelics in specific patient populations,

it's a reasonable goal. $10 million is not out of reach, because first of it's like $10 million over 10 years.

It's not like you need to write a check all at once. So that the goal for a non-profit organisation

through donations rather than investments to raise enough money to do the research, it's, it's possible.

Interview courtesy of "From Neurons to Nirvana: The Great Medicines" by Oliver Hockenhull. Film to be released later in 2012.

The Multidisciplinary Association For Psychedelic Studies
maps.org